Human E7 Peptide (YMLDLQPET) – Catalog #B2026677

The Human E7 Peptide (YMLDLQPET; Catalog #B2026677) is a peptide sequence derived from the E7 protein of human papillomavirus, supplied as 1 mg of lyophilized powder. The HPV E7 protein is a key oncoprotein that contributes to cell proliferation by interfering with the retinoblastoma (Rb) protein and other regulatory proteins. The E7 peptide YMLDLQPET is recognized by CD8+ cytotoxic T lymphocytes in HPV-infected individuals and is used in research on HPV immunity, vaccine design, and diagnostic immunoassays.

Scientific Overview

The Human E7 Peptide is derived from the HPV E7 oncoprotein, a small (~98 amino acid) viral protein that plays a critical role in HPV-mediated cell transformation and oncogenesis. E7 interacts with and destabilizes the retinoblastoma (pRb) tumor suppressor protein, leading to uncontrolled cell cycle progression and proliferation. The peptide YMLDLQPET corresponds to a region of the E7 protein that is recognized by CD8+ cytotoxic T lymphocytes (CTLs), which are crucial for immune surveillance and clearance of HPV-infected cells. In naturally infected or vaccinated individuals, E7-specific CD8+ T-cell responses are thought to be important for controlling HPV infections and preventing cervical cancer development.

Key applications include:

• Study of E7-specific CD8+ T-cell responses in HPV-positive samples
• Vaccine design and efficacy testing in HPV immunization research
• HLA-peptide binding assays to identify immunodominant epitopes
• Development of diagnostic assays to detect E7-specific immunity
• Comparative immunology studies across HPV types and variants

Usage & Handling Guidance

Reconstitute the lyophilized powder in sterile water or appropriate buffer immediately before use. The peptide is stable at the concentrations used in most immunological assays.

• Reconstitution: Dissolve in sterile water, PBS, or an appropriate culture medium at your desired concentration (typically 0.1–10 µM for immunological applications).
• Purity: The peptide is supplied in lyophilized form with high purity; request the COA for detailed analysis if needed.
• Storage: Keep the lyophilized powder at –20°C. After reconstitution, store solutions at 2–8°C for short-term use or at –20°C for longer storage.

What You Get

• 1 mg of synthesized Human E7 Peptide (YMLDLQPET)
• Lyophilized powder for convenient storage and reconstitution
• High-purity peptide suitable for immunological research
• For research use only (RUO)

Why Researchers Choose It

• Sequence derived from a known CD8+ T-cell epitope in HPV E7
• Useful for studying immune responses to HPV infection and vaccination
• Applicable to both basic immunology and translational vaccine research
• Defined chemical composition for reproducible immunoassays

Frequently Asked Questions (FAQ)

• What is the E7 protein?
  E7 is a small oncoprotein produced by human papillomavirus (HPV) that inactivates the retinoblastoma (Rb) tumor suppressor protein, contributing to uncontrolled cell proliferation and cancer development.
• Is this peptide recognized by T cells?
  Yes. The sequence YMLDLQPET is recognized by CD8+ cytotoxic T lymphocytes in HPV-infected individuals, making it a useful tool for studying immune responses to E7.
• How do I use it in an immunoassay?
  Typical applications include ELISPOT assays, flow cytometry, and peptide-HLA binding studies. Reconstitute to your working concentration and use in your chosen assay format.
• Can I get a COA?
  Yes. Request a quote or contact us and we will provide available lot documentation including purity analysis.

References

• Keskin DB, Reinhold B, Lee SY, Zhang G, Lank S, O'Connor DH, Berkowitz RS, Brusic V, Kim SJ, Reinherz EL. Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. Front Immunol. 2011;2:75.
• Nilges K, Höhn H, Pilch H, Neukirch C, Freitag K, Talbot PJ, Maeurer MJ. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol. 2003;77(9):5464-74.
• Balsitis SJ, Sage J, Duensing S, Münger K, Jacks T, Lambert PF. Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol. 2003;23(24):9094-103.